The scientists who helped launch the GLP-1 era of obesity medicine are now challenging its foundational premise. In a peer-reviewed paper published in Molecular Metabolism (April 2026), Richard DiMarchi, Matthias Tschöp and colleagues present preclinical data from rodent and non-human primate studies showing that a dual GIP-glucagon receptor agonist, administered at high doses, can achieve weight loss comparable to GLP-1-based drugs like semaglutide and tirzepatide while avoiding common gastrointestinal side effects such as nausea and vomiting. The work, funded by BlueWater Biosciences, highlights a provocative hypothesis: targeting GLP-1 may not be necessary for effective anti-obesity therapy.

This goes well beyond the STAT coverage, which frames the finding primarily as controversy within the field. What the original piece underplays is the deeper pattern of limitations emerging from large-scale human evidence on current blockbusters. Phase 3 RCTs like SURMOUNT-1 (n=2,539 adults with obesity, NEJM 2022) demonstrated 15-21% mean weight loss with tirzepatide but reported nausea in over 30% of participants and discontinuation rates approaching 20% in real-world observational cohorts. SELECT trial data (n=17,604, NEJM 2023) confirmed cardiovascular benefits yet revealed significant lean muscle loss alongside fat reduction, an outcome increasingly linked to frailty risks in long-term users. A 2024 Lancet Commission on obesity further notes that despite $100B+ in projected annual sales, these drugs fail to address root environmental drivers like ultra-processed food exposure and do not prevent near-universal weight regain upon discontinuation.

The new GIP-glucagon molecule works through different mechanisms: glucagon stimulates energy expenditure and lipolysis while GIP modulates lipid metabolism and insulin sensitivity. This contrasts with the appetite-suppression dominant paradigm of GLP-1 receptor agonists. Preclinical results, though limited by small sample sizes (typically n=10-30 per arm in such animal studies) and lack of human translation, align with earlier mechanistic work showing glucagon's thermogenic effects in a 2019 Nature Metabolism paper on energy balance. Conflicts of interest are notable—the study was industry-funded by a firm positioned to commercialize non-GLP-1 candidates.

What existing coverage has largely missed is how this fits the metabolic health crisis trajectory. Global obesity prevalence has tripled since 1975 (WHO data); current GLP-1 drugs, while transformative for many, reach fewer than 5% of eligible patients due to cost, supply constraints, and tolerability. By moving past GLP-1, this approach could reduce side-effect burden and potentially preserve muscle mass better, addressing a gap identified in 2024 Endocrine Reviews analyses of body composition changes during incretin therapy.

This does not invalidate GLP-1 success stories but signals the field's maturation. If replicated in rigorous human RCTs, it could mark the next evolution: from hormone-mimetic appetite control toward multi-pathway metabolic recalibration. History cautions optimism—many animal successes falter in clinic due to species differences in receptor biology. Yet amid stagnant progress on prevention, this line of inquiry offers genuine hope for more tolerable, accessible solutions to a crisis that continues escalating.